The study is about finding the best way to screen for liver cancer in patients with liver scarring, called cirrhosis. The two screening methods being tested are **Ultrasound (US)** and **abbreviated MRI (aMRI)**, both combined with a blood test called **serum alpha-fetoprotein (AFP)**. The goal is to catch liver cancer early, when it's easier to treat and cure. This study will help find out if using aMRI, which uses a special contrast dye and takes about 15 minutes, is better than US for early cancer detection and reducing deaths from liver cancer.
People in the study must be 18 to 75 years old, have cirrhosis, and be at high risk for liver cancer. They cannot join if they have had liver cancer before, are waiting for a liver transplant, or have certain health issues like severe liver problems or allergies to MRI dye.
Key Points:
- The study lasts for 8 years, with screenings every 6 months.
- Participants will be randomly assigned to either the US+AFP or aMRI+AFP group.
- Total of 4,700 participants are needed, and they will be recruited from 47 VA Medical Centers.
How understandable was the trial content above?
Hard to understand
Easy to understand